Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients With Adrenomyeloneuropathy

Next Previous
X
Search
Trial Profile

A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients With Adrenomyeloneuropathy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SBT 101 (Primary)
  • Indications Adrenomyeloneuropathy
  • Focus Adverse reactions; First in man
  • Acronyms PROPEL

    • Most Recent Events

    • 17 Jun 2024 According to Spur Therapeutics media release, the company Acquired SwanBio Therapeutics ,for Phase 1/2 program for adrenomyeloneuropathy to its clinical-stage pipeline and strengthening CNS expertise also the company plans to report an initial safety update from the higher-dose cohort in this trial in the first half of 2025.
    • 04 Oct 2023 According to a SwanBio Therapeutics media release, trial is currently active in the United States and is expanding into Europe following the recent approval of its Clinical Trial Application (CTA) from the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands.
    • 04 Oct 2023 According to a SwanBio Therapeutics media release, Syncona Investment Management Limited, has made an additional $10 million commitment to fund the second cohort of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top